HINDVyome Holdings Inc.
HIND
Vyome Holdings Inc.35,007
Mkt Cap
$14.74MVolume
19,911.0052W High
$33.1652W Low
$1.75PE Ratio
0.03HIND Fundamentals
Price
$2.06Prev Close
$2.10Open
$2.1450D MA
$2.32Beta
0.14Avg. Volume
20,278.90EPS (Annual)
-$4.75P/B
4.99Rev/Employee
$17,761.89$3.80
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for symptoms of Malignant Fungating Wounds (MFW) at the 2026 American Association for Cancer...
Business Wire·17d ago
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety...
Business Wire·1mo ago
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
Vyome Holdings, Inc., (Vyome) (Nasdaq: HIND), a next-generation inflammation-focused company leveraging the US-India innovation corridor, today announced its financial results and corporate and clinical milestones following its successful listing on Nasdaq. This quarter marks Vyomes first annual...
Business Wire·1mo ago
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company
Livechain, Inc. (Livechain) (OTCX: LICH), a subsidiary of Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND), announced today that it has executed a debt purchase agreement with Remus Capital, a leading...
Business Wire·2mo ago
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced the publication of its preclinical data validating the efficacy and safety of VT-1908 as a potential treatment for uveitis in the peer-reviewed...
Business Wire·3mo ago
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
Vyome Holdings, Inc. (Vyome) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it...
Business Wire·3mo ago
Independent Analyst Values Vyomes VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
Vyome Holdings, Inc. (Vyome) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced key...
Business Wire·3mo ago
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced its subsidiary, LiveChain, Inc. (Livechain or LICH) (OTC Markets: LICH) has executed a binding letter of intent (LOI) with Remus Capital, a...
Business Wire·5mo ago
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced the final results from an investigator-initiated Phase 2 proof of concept study of VT-1953 topical gel in people with malignant fungating wounds...
Business Wire·5mo ago
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
Vyome Holdings, Inc., (Vyome) (NASDAQ: HIND), a next-generation inflammation-focused company leveraging the USIndia innovation corridor, today announced its financial results and a series of...
Business Wire·6mo ago
<
1
2
...
>